INTRODUCTION {#s1}
============

Cancer cells upregulate glycolysis and increase glucose uptake to meet energy needs. A small fraction of glucose in the cell enters the hexosamine biosynthetic pathway (HBP)[@b1]--[@b3], which regulates enzymatic *O*-linked glycosylation (*O*-GlcNAcation), a carbohydrate posttranslational modification of diverse nuclear and cytosolic proteins by the addition of *O*-linked-β-*N*-acetylglucosamine(O-GlcNAc). *O*-GlcNAcation participates in the modification of protein and plays an important role in oncogenesis and progression of tumor and signal transduction[@b4]--[@b6]. GlcNAcylation plays a role in normal biological processes, and its dysregulation is involved in certain human diseases such as diabetes mellitus[@b7],[@b8] and neurologic disorders[@b9]. In recent reports, several tumor-associated proteins have been identified as GlcNAcylated proteins, including c-myc[@b10] and p53[@b11]. We hypothesized that *O*-GlcNAcylation participates in tumor occurrence. In this present study, we explored the expression of *O*-GlcNAc transferase (OGT) and *O*-GlcNAcation by immunohistochemistry using an *O*-GlcNAc-specific antibody-RL~2~ in esophageal squamous cell carcinoma. We found that the levels of both OGT and RL~2~ were high in esophageal squamous cell carcinoma, suggesting that *O*-GlcNAcylation may play an important role in esophageal squamous cell carcinoma.

SUBJECTS AND METHODS {#s2}
====================

Subjects {#s2a}
--------

We recruited 40 patients with esophageal squamous cell carcinoma, who had undergone esophagectomy between 2007 and 2009 at the Department of Thoracic Surgery, the Second Affiliated Hospital of Xi\'an Jiaotong University, Xi\'an, Shaanxi, China. Normal esophageal mucosa was got from the same patient (after the operation the esophageal mucosa was confirmed normal by pathological examination). Cancer was staged according to the 2009 UICC TNM classification. The study protocol was approved by the local Institutional Ethics Committee, and written informed consent was obtained from all the patients.

Reagents {#s2b}
--------

Rabbit polyclonal anti-OGT was bought from Protein Tech Group (Chicago, IL, USA). Mouse monoclonal anti-*O*-linked *N*-acetylglucosamine antibody (RL~2~) was bought from Thermo Scientific (Rockford, IL, USA).

Immunohistochemistry {#s2c}
--------------------

Tissues were fixed in 40 g/L paraformaldehyde, embedded in paraffin, and sectioned at a thickness of 5 µm. Sections were dewaxed, dehydrated, and then stained by SP kit (Zhongshan Goldenbridge Biotechnology Co. Ltd., Beijing, China). Antibodies of OGT and RL~2~ were diluted to a final concentration of 1:100 with TBS. OGT positive pancreatic cancer samples and RL~2~ positive gastric cancer samples were used as positive controls. Positivity of OGT or RL~2~ was considered when yellow or brown yellow granules appeared in the nucleus and cytoplasm, respectively. Samples were considered positive when more than 5% of tumor cells were stained positive, and strongly positive when more than 50% of tumor cells were stained positive. Otherwise, it was considered low expression. The positive extent was judged through density by ImagePro6.0 (Media Cybernetics, Bethesda, MD, USA), which could analyze the correlation between the expression of OGT and RL~2~.

Statistical analysis {#s2d}
--------------------

SPSS 13.0 software (SPSS Inc., Chicago, IL, USA) was used to analyze the details. The Fish\'s exact test was used to analyze the levels of OGT and RL~2~. The correlation analysis was used for the evaluation of the relationship between OGT and RL~2~. *P* values less than 0.05 were considered to be significant.

RESULTS {#s3}
=======

The demographic characteristics of subjects {#s3a}
-------------------------------------------

Forty esophageal squamous cell carcinoma patients were recruited including 28 males and 12 females. Age ranged from 40 to 77 years and the mean age was 64.6 years. None of the patients received neoadjuvant chemotherapy or radiotherapy before esophagectomy. The clinical stages were from T~2~ to T~3~ and lymph node metastasis was local. There were no distant metastatic cases.

Expression of OGT and *O*-GlcNAcation in esophageal squamous cell carcinoma {#s3b}
---------------------------------------------------------------------------

The levels of OGT and *O*-GlcNAcation in esophageal squamous cell carcinoma and normal esophageal mucosa were detected by immunohistochemistry using anti-OGT antibody and RL~2~ antibody, respectively. Most normal esophageal tissues (30/35, 85.7%) showed low expression of OGT while esophageal squamous cell carcinoma tissues mostly (35/45, 77.8%) exhibited high expression (*P* \< 0.01, [***Fig. 1A***](#jbr-26-04-268-g001){ref-type="fig"} and [***1B***](#jbr-26-04-268-g001){ref-type="fig"}, [***Table 1***](#jbr-26-04-268-t01){ref-type="table"}). Tumor size was not correlated with OGT expression (*P* = 0.78, [***Table 1***](#jbr-26-04-268-t01){ref-type="table"}). The difference in the expression of OGT between T2 and T3 stage tumors was not significant (*P* = 1.0, [***Table 1***](#jbr-26-04-268-t01){ref-type="table"}). The expression of OGT in metastatic lymph nodes or non-metastatic lymph nodes was not different (*P* = 0.627, [***Table 1***](#jbr-26-04-268-t01){ref-type="table"}). Gender and age were not correlated with OGT (*P* \> 0.05 in both, [***Table 1***](#jbr-26-04-268-t01){ref-type="table"}).

RL~2~ was positive in normal esophageal tissue, but strongly positive in esophageal squamous cell carcinoma tissues (*P* = 0.02, [***Fig. 1C***](#jbr-26-04-268-g001){ref-type="fig"} and [***1D***](#jbr-26-04-268-g001){ref-type="fig"}, [***Table 2***](#jbr-26-04-268-t02){ref-type="table"}). The samples with lymph node metastasis showed higher RL~2~ expression compared to samples without lymph node metastasis (*P* = 0.046, [***Table 2***](#jbr-26-04-268-t02){ref-type="table"}). Tumor size, T stage, gender and age were not correlated with RL~2~ positive status (*P* \> 0.05 in all, [***Table 2***](#jbr-26-04-268-t02){ref-type="table"}). According to the optical density analyzed by ImagePro6.0, in samples with lymph node metastasis, the optical density of OGT was 250.3±16.28, and that of RL~2~ was 171.5±16.18. The density of RL~2~ was positively correlated with OGT (*r* = 0.996, *P* = 0.028).

![OGT and RL~2~ expression in normal and esophageal squamous cell carcinoma (SP staining, ×100).\
A: Expression of OGT in normal esophageal mucosa. B: Expression of OGT in esophageal squamous cell carcinoma. C: Expression of *O*-GlcNAc in normal esophageal mucosa. D: Expression of *O*-GlcNAc in esophageal squamous cell carcinoma.](jbr-26-04-268-g001){#jbr-26-04-268-g001}

###### Relationship between OGT expression and pathologic features of esophageal cancer patients

  Pathological factor         Low expression of OGT   High expression of OGT   *P* value
  -------------------------- ----------------------- ------------------------ -----------
  Sample source                                                               
  Esophageal cancer                     5                       35                 0
  Normal esophageal mucosa             30                       10            
  T stage                                                                     
   T2                                   1                       20                1.0
   T3                                   4                       15            
  Length of cancer                                                            
   \> 5 cm                              2                       22               0.78
   \< 5 cm                              3                       13            
  Lymph node metastasis                                                       
   (+)                                  3                       25               0.627
   (--)                                 2                       10            
  Gender                                                                      
   Male                                 3                       25               0.627
   Female                               2                       10            
  Age (years)                                                                 
   \< 50                                1                       18               0.345
   \> 50                                4                       17            

(*n* = 40)

###### Relationship between RL~2~ level and pathologic features in esophageal cancer patients

  Pathological factor         Low expression of RL~2~   High expression of RL~2~   *P* value
  -------------------------- ------------------------- -------------------------- -----------
  Sample source                                                                   
  Esophageal cancer                     10                         30                0.02
  Normal esophageal mucosa              25                         15             
  T stage                                                                         
   T2                                    7                         14                0.181
   T3                                    3                         16             
  Length of cancer                                                                
   \> 5 cm                               4                         20                0.159
   \< 5 cm                               6                         10             
  Lymph node metastasis                                                           
   (+)                                   5                         23                0.046
   (--)                                  6                         6              
  Gender                                                                          
   Male                                  6                         22                0.451
   Female                                4                         8              
  Age (years)                                                                     
   \< 50                                 4                         15                0.721
   \> 50                                 6                         15             

(*n* = 20)

DISCUSSION {#s4}
==========

Protein modification includes phosphorylation, glycosylation, ubiquitination, glycosylation, nitrolation, and *O*-GlcNAcation. *O*-GlcNAcation is a kind of carbohydrate posttranslational modification of diverse nuclear and cytosolic proteins, which is the post-translational cycling of a single *O*-linked-β-*N*-acetylglucosamine on the hydroxyl groups of serine and/or threonine residues of target proteins[@b5],[@b12],[@b13]. O-GlcNAcylation is dynamically regulated by OGT and β-N-acetylglucosaminidase (OGA). OGT (polypeptide β-N-acetylglucosaminyltransferase) catalyzes the addition of O-linked-β-N-acetylglucosamine from UDP-GlcNAc onto the hydroxyl group of a serine or a threonine residue on the protein substrates[@b14]. OGA is a neutral hexosaminidase with a catalytic site similar to that of the family 84 glycoside hydrolase that specifically catalyzes the removal of β-linked GlcNAc on its substrate[@b15],[@b16],[@b17].

When *O*-GlcNAcation modifies the protein, it can regulate phosphorylation of substrates at the same time, so there should be some relationships between phosphorylation and *O*-GlcNAcation[@b18]. A study showed that *O*-GlcNAcation competed with phosphorylation[@b19]. In fact, most of cellular signal transduction was related to the phosphorylation of proteins, so the level of cellular *O*-GlcNAcation may affect cellular signal transduction. Abnormal cellular signal transduction is one of the reasons for the occurrence and development of cancer.

Our study showed that OGT expression and *O*-GlcNAcation level were both increased in esophageal squamous cell carcinoma tissues compared to normal esophageal mucosa tissues (*P* \< 0.05). Similar results have been reported in lung and colon cancer[@b20]. *O*-GlcNAcation of protein usually competes with phosphorylation of protein[@b21]. As long as the protein is GlcNAcylated, protein degradation through the phosphorylation pathway is inhibited, and then GlcNAcylated protein becomes stable. Some oncoproteins, such as p53 and c-myc, which also can be GlcNAcylated, become stable after GlcNAcylation and are increased inside the cells[@b22],[@b23], and then activate abnormal cellular signal transduction[@b23],[@b24],[@b25]. In hepatocellular carcinoma followed by liver transplantation, O-GlcNAcylation was significantly enhanced in the tumor tissues of patients, who suffered from recurrence of hepatocellular carcinoma[@b26], suggesting that the level of O-GlcNAcation in hepatocellular carcinoma might be related to tumor reccurrence. In our study, the length, age, gender and T stage of cancer did not affect the levels of OGT and O-GlcNAcation (P \> 0.05, [***Table 1***](#jbr-26-04-268-t01){ref-type="table"}, [2](#jbr-26-04-268-t02){ref-type="table"}). These results support the opinion that the level of O-GlcNAcation might be related to the cancerous occurrence.

In fact, *O*-GlcNAcation is regulated by OGT and OGA. Slawson *et al*.[@b28] found that the activity of OGA was higher in breast cancer, especially in more aggressive tumors. By contrast, tumor cell lines that mimic metastatic tumors showed an increase in OGT expression and *O*-GlcNAcation, suggesting that an increase in *O*-GlcNAcylation may be beneficial to cancer cells[@b29]. So there is a conflict between OGT and OGA in breast cancer. We also investigated the expression of OGA in esophageal squamous cell carcinoma, but the result shows that there is no difference between expression in normal esophageal tissue and esophageal squamous cell carcinoma. Our statistical analysis showed that OGT was highly expressed in esophageal squamous cell carcinoma, and was positively correlated with *O*-GlcNAcation (*r* = 0.996, *P* = 0.028). The results indicated that OGT promoted *O*-GlcNAcation and played a more important role than OGA in esophageal squamous cell carcinoma, suggesting that in esophageal squamous cell carcinoma, OGT was the main protein responsible for *O*-GlcNAcation. In fact, high expression of OGT not only promotes the level of cellular *O*-GlcNAcation, but also affects cancerous occurrence. The TPR domain of OGT could promote protein interactions and affect the function of spindle[@b30]. This process produces many aneuploid cells, which result in tumor occurrence[@b31].

In our study, RL~2~ is strongly positive in the cancer samples with lymph node metastasis compared with those with no lymph node metastasis (*r* = 0.996, *P* = 0.046), suggesting that the high level of *O*-GlcNAcation is conducive to the metastasis of esophageal squamous cell carcinoma, especially to lymph nodes. This phenomenon has been observed in breast cancer[@b32]. Gu found that GlcNAcylated p120 and β-catenin affect the metastasis of breast cancer, especially in lymph node metastasis^\[33\]^.

In brief, based on our study, we concluded that high expression of OGT promoted the increase of *O*-GlcNAcation in esophageal squamous cell carcinoma and the high level of *O*-GlcNAcation may stabilize proteins, leading to changes in cellular signal transduction and resulting tumorigenesis and metastasis. Decreasing *O*-GlcNAcation by inhibiting OGT may benefit treatment of esophageal squamous cell carcinoma.
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